TABLE 3.

Adverse events of special interest during cycle 1

Characteristic	ACC Cohort	GC, EGC, and SCLC Cohorts a
Infusion process	4 step b	2 step c	2 step c	2 step c
Premedication	Steroid + antihistamine	Steroid + antihistamine	Antihistamine	None
n	12	11	10	10
Patients with any hypersensitivity reaction, n (%)	1 (8.3)	0	2 (20.0)	2 (20.0)
Grade 1	1 (8.3)	0	1 (10.0)	0
Grade 2	0	0	1 (10.0)	2 (20.0)
Grade 3	0	0	0	0
Grade 4	0	0	0	0

Abbreviations: ACC, adenoid cystic carcinoma; EGC, esophageal carcinoma; GC, gastric carcinoma; SCLC, small cell lung cancer.

^a The first 10 patients enrolled in the GC, EGC, and SCLC cohorts were to receive steroid + antihistamine premedication; the next 10 patients enrolled were to receive only antihistamine premedication; the remaining patients enrolled were not to receive any premedication, regardless of tumor type.

^b The 4‐step E7389‐LF infusion rate: 0.005 mg/min, 0.01 mg/min, and 0.02 mg/min for ≥10 min each, followed by ≤0.2 mg/min.

^c The 2‐step E7389‐LF infusion rate: 0.01 mg/min for ≥10 min, followed by 0.1 mg/min.